JuliaR
@jromanowska@fosstodon.org  ·  activity timestamp last week
JuliaR
@jromanowska@fosstodon.org  ·  activity timestamp last week
WikiPathways
@wikipathways@fosstodon.org  ·  activity timestamp last week
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
WikiPathways
@wikipathways@fosstodon.org  ·  activity timestamp last week
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathways, GABA and glutamate signalling in epileptogenesis (WP5600): This pathway depicts the epileptogenic mechanisms involving GABA and glutamate signaling. It focuses on transporters and channel proteins that modulate action potential dynamics and their interacting partners, highlighting functional alterations that contribute to epilepsy pathogenesis.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
New pathway, Caffeine in blood vessels (WP5601). In vascular smooth muscle, caffeine promotes relaxation by inhibiting myosin light-chain kinase (MLCK) through cAMP elevation and activating myosin light-chain phosphatase (MLCP), reducing myosin–actin interaction. As a nonselective adenosine receptor antagonist, caffeine blocks A₁/A₃ receptors (which normally lower cAMP) and A₂A/A₂B receptors (which normally raise cAMP), thereby altering adenylate cyclase activity. In endothelial cells, caffeine increases intracellular Ca²⁺, activating eNOS to produce nitric oxide (NO), which diffuses to smooth muscle and stimulates cGMP signaling, further promoting vasodilation. Inspired by Figure 1 in Kumar and Lipshultz, 2019.
The BridgeDb Project
@bridgedb@fosstodon.org  ·  activity timestamp 2 weeks ago
The BridgeDb Project
@bridgedb@fosstodon.org  ·  activity timestamp 2 weeks ago
d@nny disc@ mc² and 1 other boosted
Samuel Lampa
@shl@genomic.social  ·  activity timestamp 2 weeks ago
Samuel Lampa
@shl@genomic.social  ·  activity timestamp 2 weeks ago
NFDI4Microbiota
@NFDI4Microbiota@nfdi.social  ·  activity timestamp 2 weeks ago
NFDI4Microbiota
@NFDI4Microbiota@nfdi.social  ·  activity timestamp 2 weeks ago
Christos Argyropoulos
@ChristosArgyrop@mast.hpc.social  ·  activity timestamp 3 weeks ago
Christos Argyropoulos
@ChristosArgyrop@mast.hpc.social  ·  activity timestamp 3 weeks ago
Brian Repko
@brianrepko@hachyderm.io  ·  activity timestamp 3 weeks ago
Brian Repko
@brianrepko@hachyderm.io  ·  activity timestamp 3 weeks ago
Billy Smith and 1 other boosted
Peter Cock
@pjacock@fediscience.org  ·  activity timestamp 4 weeks ago
Peter Cock
@pjacock@fediscience.org  ·  activity timestamp 4 weeks ago
Home Login